company-logo

SOL S.p.A. engages in the applied research, production, and marketing of technical and medical gases; and in home medical assistance and related medical equipment in Italy and internationally. The company offers technical and medical gases, including oxygen, nitrogen, argon, hydrogen, carbon and sulphur dioxide, acetylene, nitrous oxide, gas mixtures, high purity gases, food gases, and gaseous and liquid helium; gas for electronics; and ammonia and combustible gases for industrial use. It also provides home oxygen therapy, home mechanical ventilation, and aerosol therapy services, as well as the diagnosis and treatment of respiratory sleep disorders; services for artificial nutrition, insulin therapy with pumps, and immunotherapy, as well as services for the treatment of pain and Parkinson's disease; home healthcare and social care services; telemedicine and digital services; and healthcare aids. In addition, it provides medical devices; training services; InfoHealth SOLution, a web platform that allows to control plans, coordinate, and manage the activities; electromedical equipment services; hospital hygiene and environmental monitoring services; and ambulance management services. Further, it designs, constructs, and manages bio banks; distribution of medical and technical gases; produces and sells hydroelectric power; offers pre-and post-natal diagnostic screening services; produces and sells diagnostic systems; researches, develops, and markets products for research, diagnosis and clinical application in the hospital, environmental, veterinary and food sectors; and bioshipping services, as well as provides transfer, storage, and handling services of biological samples. Its products are used in the chemical, electronics, steel, metal, and food industries, as well as in environmental protection, and research and healthcare sectors. The company was founded in 1927 and is headquartered in Monza, Italy. SOL S.p.A. is a subsidiary of Gas and Technologies World BV.

SOL Dividend Announcement

SOL announced a annually dividend of €0.37 per ordinary share which will be made payable on 2024-05-22. Ex dividend date: 2024-05-20
SOL annual dividend for 2024 was €0.37
SOL annual dividend for 2023 was €0.33
SOL's trailing twelve-month (TTM) dividend yield is 1.0%
SOL's payout ratio for the trailing twelve months (TTM) is 28.92%
SOL's dividend growth over the last five years (2018-2023) was 17.08% year
SOL's dividend growth over the last ten years (2013-2023) was 12.68% year

SOL Dividend History

Ex-Div dateDividend amountDividend typePay date
2024-05-20€0.37annually2024-05-22
2023-05-22€0.33annually
2022-05-16€0.24annually
2021-05-24€0.22annually
2021-05-17€0.22annually
2020-05-25€0.17annually
2020-05-18€0.17annually
2019-05-20€0.17annually
2018-05-21€0.15annually
2017-05-22€0.15annually
2016-05-23€0.12annually
2015-05-18€0.11annually
2014-05-19€0.10annually
2013-05-20€0.10annually

SOL Dividend per year

SOL Dividend growth

SOL Dividend Yield

SOL current trailing twelve-month (TTM) dividend yield is 1.0%. Interested in purchasing SOL stock? Use our calculator to estimate your expected dividend yield:

SOL Financial Ratios

P/E ratio19.21
PEG ratio-1.09
P/B ratio3.46
ROE18.33%
Payout ratio28.92%
Current ratio2.09
Quick ratio1.83
Cash Ratio0.50

SOL Dividend FAQ

Does SOL stock pay dividends?
SOL does not currently pay dividends to its shareholders.
Has SOL ever paid a dividend?
No, SOL has no a history of paying dividends to its shareholders. SOL is not known for its dividend payments.
Why doesn't SOL pay dividends?
There are several potential reasons why SOL would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will SOL ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While SOL has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is SOL a dividend aristocrat?
SOL is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is SOL a dividend king?
SOL is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is SOL a dividend stock?
No, SOL is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy SOL stocks?
To buy SOL you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy SOL stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.